What to Expect With YUTIQ: YUTIQ®(fluocinolone acetonide intravitreal implant) 0.18 mg

Expectations With YUTIQ

About the YUTIQ procedure

YUTIQ^® (fluocinolone acetonide intravitreal implant) 0.18 mg is administered by an eye doctor during a simple in-office procedure.

BEFORE your posterior segment uveitis treatment begins, your eye will be prepared for the procedure as follows: The eye receiving the implant is propped open with a device called a speculum (pronounced Spek-YOU-Lum), your eye is numbed with numbing drops, and topical antiseptic is applied.

DURING your procedure, the YUTIQ implant will be inserted with a tiny needle. As the implant is injected, you may feel pressure on your eye.

AFTER your procedure, your eye will be monitored for possible side effects, such as pressure in your eye, right after the implant is inserted and then again 2 to 7 days later. It’s important to keep up with regularly scheduled visits so your eye doctor can carefully monitor your condition.

Some of the common side effects in more than 10% of patients treated with YUTIQ are cataracts, reduced visual acuity (unclear vision), and macular edema (swelling around the retina).

It is recommended that you bring a caregiver or family member to your procedure to drive you home afterward. You may experience temporary visual blurring after receiving the YUTIQ injection. DO NOT drive or use machinery until this has been resolved.

Short procedure, lasting results—the YUTIQ implant is inserted in the eye doctor’s office and is designed to deliver a low dose of steroid for up to 36 months.

I felt it was a relatively simple procedure…in fact, the entire process was over before I knew it.

– Vickie, a YUTIQ patient

Talk with your retina or uveitis specialist about treatment with YUTIQ. Don’t have a retina specialist? Find one here.

*People pictured are not real patients unless otherwise noted.

INDICATION AND USAGE

YUTIQ^® (fluocinolone acetonide intravitreal implant) 0.18 mg contains a corticosteroid and is for the treatment of patients with chronic, non-infectious uveitis affecting the back of the eye.

IMPORTANT SAFETY INFORMATION

Do not take YUTIQ if:

You have, or suspect you have, an eye infection
If you have been told you are allergic to any of the ingredients in YUTIQ

YUTIQ may cause serious side effects, including:

Injection-related effects, steroid-related effects and movement of the implant.

Call your doctor if your eye becomes red, sensitive to light, painful or if your vision changes or becomes blurred.

You may experience temporary blurred vision. Do not drive or use machines until your vision clears.

The most common side effects in the eye were cataract and reduced clarity of vision. The most common side effects not related to the eye were upper respiratory infection, high blood pressure and joint pain.

If you are pregnant, become pregnant or consider breastfeeding after having received YUTIQ inform your doctor immediately.

Please see full Prescribing Information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1‑800‑FDA‑1088.

YUTIQ, the YUTIQ logo, and the EyePoint logo are registered trademarks of EyePoint Pharmaceuticals, Inc. EyePoint Assist is a service mark of EyePoint Pharmaceuticals, Inc.

480 Pleasant Street, Suite B300, Watertown, MA 02472

12/2022

US-YUT-2200116

INDICATION AND USAGE

YUTIQ^® (fluocinolone acetonide intravitreal implant) 0.18 mg contains a corticosteroid and is for the treatment of patients with chronic, non-infectious uveitis affecting the back of the eye.

IMPORTANT SAFETY INFORMATION

Do not take YUTIQ if:

You have, or suspect you have, an eye infection
If you have been told you are allergic to any of the ingredients in YUTIQ

Are you an eye care professional in the US?

By following this link, you will visit a site maintained by a third party who is responsible for its content. This link is not owned or operated by EyePoint Pharmaceuticals, Inc.